Skip to main content

14-06-2020 | ADA 2020 | Conference coverage | Video

Expert commentary: Icosapent ethyl lowers cardiovascular risk in people with diabetes

Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).

Read the transcript

Related content

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »